The Processes Needed for Successful Pharmaceutical Forecasting
Many pharmaceutical companies are harnessing digital solutions to elevate global forecasting. Digital tools, such as cloud-based, SaaS environments, are powering efficient, streamlined, and intelligent forecasting processes. But, for technological solutions to empower pharma, there need to be robust forecasting processes in place to make them work in alignment with your business goals. Why are Forecasting […]
Who’s winning in the battle for efficient capital deployment?
Over the last ten years, large pharma companies have spent an average of $120bn across R&D and business development investments. The net result? Portfolios worth approximately $210bn, according to Evaluate’s net present value (NPV) methodology. However, within these averages lie dramatically diverging performances, highlighting the challenges of deploying capital efficiently. Overall company performance is heavily […]
What’s Behind Pharma’s Growth Boost?
One of the milestones in the Evaluate year is the publication of our annual World Preview report, now in its 17th year. If you’re not familiar with the piece, it’s a deep dive into the state of the biopharma market, using Evaluate’s pharma forecasts to uncover key trends, challenges and drivers of growth (or indeed […]
In Case You Missed It: Three Things we Learned in our Orphan Drugs Webinar
If you missed our recent webinar in which we dived in the orphan drugs landscape, you skipped a fascinating discussion between biopharma journalist Melanie Senior, author of our recent report “Have Orphans Lost Their Sparkle?”, Evaluate analyst Puru Gaur and special guest Stephanie Léouzon, Managing Director, Biopharma Healthcare at Stifel. The good news is that […]
The Future of Pharma Forecasting
What is FC365? In the fast-paced and ever-evolving world of pharmaceutical forecasting, having access to modern, high-performing tools is crucial. FC365 is addressing the industry’s unique needs, empowering forecasting teams to work more effectively and efficiently. Implementation of this SaaS platform across many leading pharma is now streamlining processes and bringing efficiencies. Saving teams valuable […]
Neurology’s Renewal
In the realm of healthcare, neurology is experiencing a revival, marked by notable clinical advancements, increased deal activity, and a resurgence of interest from pharmaceutical giants. While perhaps not as widely discussed as topics like obesity, neuroscience’s return to the spotlight is evident through various indicators, including rising deal numbers and significant mergers and acquisitions. […]
Orphans are Getting Strategic
You may have read the new report we recently published on the orphan drug market. Rare diseases and their therapies are a huge topic to cover so inevitably, we couldn’t cover everything in the report. However, that’s what webinars are for! I’m delighted to be taking part in Evaluate’s upcoming webinar which will explore the […]
What’s the Deal? Navigating the Complex World of Pharma Business Development
2024 has the potential to be a year full of partnering opportunities, driven by the much-discussed patent cliff as some of the biggest-selling drugs in history are set to lose exclusivity by 2028. Perhaps as much as 6% of the nearly $1.6 trillion overall drug market might be at risk and while this isn’t Big […]
Meet the Team: Andrew Ward
If you missed the recent news, Evaluate recently acquired J+D Forecasting, a provider of brilliant forecasting solutions to pharma and biotech companies. Andrew Ward has been with the J+D team for almost 10 years as Head of Implementation team, ensuring that the team is able to meet the ever-evolving needs of their customers. I grabbed […]
Orphan Drug Report 2024: Slowdown a Sign of Success
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the case for why it is essential biopharma reading below. And while I have your attention, you can grab your complimentary copy of Orphan Drug Report […]
